Nanjing Legend Biotech

Best Biotech News Sources: How Legend Biotech Emerged as a Rare Market Winner

6 min

Legend Biotech shares soared over 40% after disclosing early in vivo CAR-T data in Non-Hodgkin's lymphoma. This analysis explains the development, implications for pharma teams, and key milestones to track.

Legend Biotech surges on early in vivo CAR-T data for lymphoma

cell therapy · 5 min

Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.

Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis

8 min

Legend Biotech's stock experienced a significant surge following the release of initial in vivo CAR-T cell therapy data. This development signals a potential shift in the CAR-T landscape, with implications for manufacturing, accessibility, and competitive dynamics.

Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO

7 min

Legend Biotech has presented significant new data at ASCO 2026, showcasing updated survival and safety results for its multiple myeloma therapy CARVYKTI from the CARTITUDE-4 study. The company also unveiled first-in-human data for its investigational CAR-T cell therapy, LB2102, targeting solid tumors.